Avenzo Therapeutics is developing targeted oncology therapies that utilize novel drug delivery systems to improve the efficacy of cancer treatments. The company focuses on addressing the limitations of current therapies by advancing a pipeline of potentially best-in-class options for patients with serious diseases.
Funding
$385.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often suffer from limitations in efficacy due to non-specific drug delivery, leading to systemic toxicity and reduced therapeutic impact on tumors. This necessitates the development of more targeted approaches to maximize drug concentration at the tumor site while minimizing off-target effects.
Solution
Avenzo Therapeutics is developing a pipeline of targeted oncology therapies designed to improve the efficacy and safety profiles of cancer treatments. The company utilizes novel drug delivery systems to selectively target tumor cells, enhancing drug accumulation within the tumor microenvironment. By focusing on precision medicine, Avenzo aims to overcome the limitations of conventional chemotherapy and radiation, offering potentially best-in-class treatment options for patients with serious diseases. Their approach seeks to maximize therapeutic benefit while minimizing systemic toxicity, ultimately improving patient outcomes.
Target Audience
The primary target audience includes patients with serious cancers, oncologists, and clinical researchers seeking more effective and less toxic treatment options.
Features
- Novel drug delivery systems for targeted drug release within the tumor microenvironment
- Pipeline of oncology therapies focused on addressing limitations of current treatments
- Development of potentially best-in-class options for patients with serious diseases